Anti-C1q Fab Fragments for Selective Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, including protein drugs and low molecular weight/small molecule inhibitors, suffer from issues such as poor tissue penetration, high toxicity, low potency, poor selectivity, and immunogenicity, making them ineffective for treating inflammatory and neurodegenerative diseases associated with complement activation.
Innovation Solution
Development of an antibody Fab fragment that binds to C1q, comprising specific heavy and light chain domains, which is designed for higher tissue penetration, reduced immunogenicity, and effective inhibition of the complement cascade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein drugs or low molecular weight inhibitors are used as complement inhibitors, then complement activation can be inhibited, but tissue penetration is poor and toxicity is high
Solution Approach 1:
The patent segments the antibody structure by using only the Fab fragment (antigen-binding portion) rather than the complete antibody molecule. This segmentation removes the Fc region that mediates effector functions, thereby reducing immunogenicity and toxicity while preserving complement inhibition capability through the intact variable regions that bind C1q.
Solution Approach 2:
The invention extracts and utilizes only the essential antigen-binding Fab fragment from the complete antibody structure. By taking out the Fc portion responsible for unwanted immunogenic effects and isolating the Fab fragment that contains the C1q-binding capability, the patent achieves reduced toxicity while maintaining therapeutic efficacy.
2Reliability
If complete antibodies are used to inhibit complement activation, then complement cascade inhibition is effective, but immunogenicity increases
Solution Approach 1:
The patent segments the antibody into Fab and Fc portions, using only the Fab fragment for therapeutic application. This segmentation eliminates the Fc region that is primarily responsible for immunogenic responses, while the Fab fragment retains the ability to bind C1q and inhibit complement activation.
Solution Approach 2:
The invention extracts the immunogenic Fc portion from the complete antibody structure and utilizes only the non-immunogenic Fab fragment that contains the essential C1q-binding function. This extraction approach reduces immunogenicity while preserving the therapeutic mechanism of action.
3Reliability
If conventional complement inhibitors are used, then complement activation is inhibited, but selectivity is poor leading to off-target effects
Solution Approach 1:
The patent applies local quality by engineering the Fab fragment with specific affinity and specificity for C1q through optimized variable regions. This localized optimization of binding characteristics at the antigen-binding site enhances selectivity for the complement system while minimizing off-target effects on other physiological pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody Fab fragment effectively inhibits complement activation, providing therapeutic benefits for neurodegenerative disorders and inflammatory conditions by reducing synapse loss and tissue damage, with improved tissue penetration and lower immunogenicity compared to existing inhibitors.
Implementation Method 1
an antibody Fab fragment that binds to C1q, comprising a heavy chain domain and a light chain domain
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.